1
|
Di Francesco L, Bruno A, Ricciotti E, Tacconelli S, Dovizio M, Guillem-Llobat P, Alisi MA, Garrone B, Coletta I, Mangano G, Milanese C, FitzGerald GA, Patrignani P. Pharmacological Characterization of the Microsomal Prostaglandin E 2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo. Front Pharmacol 2020; 11:374. [PMID: 32317963 PMCID: PMC7147323 DOI: 10.3389/fphar.2020.00374] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Accepted: 03/12/2020] [Indexed: 12/14/2022] Open
Abstract
Rationale The development of inhibitors of microsomal prostaglandin (PG)E2 synthase-1 (mPGES-1) was driven by the promise of attaining antiinflammatory agents with a safe cardiovascular profile because of the possible diversion of the accumulated substrate, PGH2, towards prostacyclin (PGI2). Objectives We studied the effect of the human mPGES-1 inhibitor, AF3485 (a benzamide derivative) on prostanoid biosynthesis in human whole blood in vitro. To characterize possible off-target effects of the compound, we evaluated: i)the impact of its administration on the systemic biosynthesis of prostanoids in a model of complete Freund's adjuvant (CFA)-induced monoarthritis in rats; ii) the effects on cyclooxygenase (COX)-2 expression and the biosynthesis of prostanoids in human monocytes and human umbilical vein endothelial cells (HUVECs) in vitro. Methods Prostanoids were assessed in different cellular models by immunoassays. The effect of the administration of AF3485 (30 and 100 mg/kg,i.p.) or celecoxib (20mg/kg, i.p.), for 3 days, on the urinary levels of enzymatic metabolites of prostanoids, PGE-M, PGI-M, and TX-M were assessed by LC-MS. Results In LPS-stimulated whole blood, AF3485 inhibited PGE2 biosynthesis, in a concentration-dependent fashion. At 100μM, PGE2 levels were reduced by 66.06 ± 3.30%, associated with a lower extent of TXB2 inhibition (40.56 ± 5.77%). AF3485 administration to CFA-treated rats significantly reduced PGE-M (P < 0.01) and TX-M (P < 0.05) similar to the selective COX-2 inhibitor, celecoxib. In contrast, AF3485 induced a significant (P < 0.05) increase of urinary PGI-M while it was reduced by celecoxib. In LPS-stimulated human monocytes, AF3485 inhibited PGE2 biosynthesis with an IC50 value of 3.03 µM (95% CI:0.5–8.75). At 1μM, AF3485 enhanced TXB2 while at higher concentrations, the drug caused a concentration-dependent inhibition of TXB2. At 100 μM, maximal inhibition of the two prostanoids was associated with the downregulation of COX-2 protein by 86%. These effects did not involve AMPK pathway activation, IkB stabilization, or PPARγ activation. In HUVEC, AF3485 at 100 μM caused a significant (P < 0.05) induction of COX-2 protein associated with enhanced PGI2 production. These effects were reversed by the PPARγ antagonist GW9662. Conclusions The inhibitor of human mPGES-1 AF3485 is a novel antiinflammatory compound which can also modulate COX-2 induction by inflammatory stimuli. The compound also induces endothelial COX-2-dependent PGI2 production via PPARγ activation, both in vitro and in vivo, which might translate into a protective effect for the cardiovascular system.
Collapse
Affiliation(s)
- Luigia Di Francesco
- Department of Neuroscience, Imaging and Clinical Sciences, and Center for Advanced Studies and Technology (CAST), School of Medicine, G. d'Annunzio University, Chieti, Italy
| | - Annalisa Bruno
- Department of Neuroscience, Imaging and Clinical Sciences, and Center for Advanced Studies and Technology (CAST), School of Medicine, G. d'Annunzio University, Chieti, Italy
| | - Emanuela Ricciotti
- Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, United States
| | - Stefania Tacconelli
- Department of Neuroscience, Imaging and Clinical Sciences, and Center for Advanced Studies and Technology (CAST), School of Medicine, G. d'Annunzio University, Chieti, Italy
| | - Melania Dovizio
- Department of Neuroscience, Imaging and Clinical Sciences, and Center for Advanced Studies and Technology (CAST), School of Medicine, G. d'Annunzio University, Chieti, Italy
| | - Paloma Guillem-Llobat
- Department of Neuroscience, Imaging and Clinical Sciences, and Center for Advanced Studies and Technology (CAST), School of Medicine, G. d'Annunzio University, Chieti, Italy
| | | | | | | | | | | | - Garret A FitzGerald
- Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, United States
| | - Paola Patrignani
- Department of Neuroscience, Imaging and Clinical Sciences, and Center for Advanced Studies and Technology (CAST), School of Medicine, G. d'Annunzio University, Chieti, Italy
| |
Collapse
|
2
|
Travelli C, Aprile S, Mattoteia D, Colombo G, Clemente N, Scanziani E, Terrazzino S, Alisi MA, Polenzani L, Grosa G, Genazzani AA, Tron GC, Galli U. Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group. Eur J Med Chem 2019; 181:111576. [PMID: 31400709 DOI: 10.1016/j.ejmech.2019.111576] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Revised: 07/29/2019] [Accepted: 07/30/2019] [Indexed: 12/14/2022]
Abstract
The enzyme nicotinamide phosphoribosyltransferase is both a key intracellular enzyme for NAD biosynthesis (iNAMPT) and an extracellular cytokine (eNAMPT). The relationship between this latter role and the catalytic activity of the enzyme is at present unknown. With the intent of discovering inhibitors specifically able to target eNAMPT, we increased the polarity of MV78 (EC50 = 5.8 nM; IC50 = 3.1 nM), a NAMPT inhibitor previously discovered by us. The replacement of a phenyl ring with a 1,2,3-triazole bearing a protonable N,N-dialkyl methanamine group gave a series of molecules which maintained the inhibition of the enzymatic activity but were unable to cross the plasma membrane and affect cell viability in vitro. Compounds 30b and 30f can therefore be considered as the first experimental/pharmacological tools for scientists that wish to understand the role of the catalytic activity of eNAMPT. Serendipitously, we also discovered a compound (25) which, notwithstanding its high polarity, was able to cross the plasma membrane being cytotoxic, a potent NAMPT inhibitor and effective in reducing growth of triple negative mammary carcinoma in mice. In our hands, 25 lacked retinal and cardiac toxicity, although we observed a lesser toxicity of NAMPT inhibitors in general compared to other reports.
Collapse
Affiliation(s)
- Cristina Travelli
- Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy; Dipartimento di Scienze del Farmaco, Università degli Studi di Pavia, Viale Taramelli 12, 27100, Pavia, Italy
| | - Silvio Aprile
- Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy
| | - Daiana Mattoteia
- Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy
| | - Giorgia Colombo
- Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy
| | - Nausicaa Clemente
- Dipartimento di Scienze della Salute and IRCAD, Università degli Studi del Piemonte Orientale, Via Solaroli 17, 28100, Novara, Italy
| | - Eugenio Scanziani
- Dipartimento di Medicina Veterinaria, Università degli Studi di Milano, Via Celoria 10, 20133, Milano, Italy; Mouse and Animal Pathology Lab (MAPLab), Fondazione Università degli Studi di Milano, Viale Ortles 22/4, 20139, Milano, Italy
| | - Salvatore Terrazzino
- Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy
| | - Maria Alessandra Alisi
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A, Piazzale della Stazione Snc, 00071, S. Palomba, Roma, Italy
| | - Lorenzo Polenzani
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A, Piazzale della Stazione Snc, 00071, S. Palomba, Roma, Italy
| | - Giorgio Grosa
- Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy
| | - Armando A Genazzani
- Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy
| | - Gian Cesare Tron
- Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy
| | - Ubaldina Galli
- Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy.
| |
Collapse
|
3
|
Furlotti G, Alisi MA, Cazzolla N, Ceccacci F, Garrone B, Gasperi T, La Bella A, Leonelli F, Loreto MA, Magarò G, Mangano G, Bettolo RM, Masini E, Miceli M, Migneco LM, Vitiello M. Targeting Serotonin 2A and Adrenergic α 1 Receptors for Ocular Antihypertensive Agents: Discovery of 3,4-Dihydropyrazino[1,2-b]indazol-1(2H)-one Derivatives. ChemMedChem 2018; 13:1597-1607. [PMID: 29873449 DOI: 10.1002/cmdc.201800199] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 05/18/2018] [Indexed: 01/29/2023]
Abstract
Glaucoma affects millions of people worldwide and causes optic nerve damage and blindness. The elevation of the intraocular pressure (IOP) is the main risk factor associated with this pathology, and decreasing IOP is the key therapeutic target of current pharmacological treatments. As potential ocular hypotensive agents, we studied compounds that act on two receptors (serotonin 2A and adrenergic α1 ) linked to the regulation of aqueous humour dynamics. Herein we describe the design, synthesis, and pharmacological profiling of a series of novel bicyclic and tricyclic N2-alkyl-indazole-amide derivatives. This study identified a 3,4-dihydropyrazino[1,2-b]indazol-1(2H)-one derivative with potent serotonin 2A receptor antagonism, >100-fold selectivity over other serotonin subtype receptors, and high affinity for the α1 receptor. Moreover, upon local administration, this compound showed superior ocular hypotensive action in vivo relative to the clinically used reference compound timolol.
Collapse
Affiliation(s)
- Guido Furlotti
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A., Piazzale della stazione snc, 00071, S. Palomba-Pomezia (Rome), Italy
| | - Maria Alessandra Alisi
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A., Piazzale della stazione snc, 00071, S. Palomba-Pomezia (Rome), Italy
| | - Nicola Cazzolla
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A., Piazzale della stazione snc, 00071, S. Palomba-Pomezia (Rome), Italy
| | - Francesca Ceccacci
- Chemistry Department "S. Cannizzaro", University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy.,Current affiliation: Istituto di Metodologie Chimiche-CNR, Unità Organizzativa di Supporto, Sede di Roma, Università degli Studi di Roma "La Sapienza", P. le Aldo Moro 5, 00185, Rome, Italy)
| | - Beatrice Garrone
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A., Piazzale della stazione snc, 00071, S. Palomba-Pomezia (Rome), Italy
| | - Tecla Gasperi
- Department of Science, Section of Nanoscience and Nanotechnology, University of Roma Tre, via della Vasca Navale 79, 00146, Rome, Italy
| | - Angela La Bella
- Chemistry Department "S. Cannizzaro", University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy
| | - Francesca Leonelli
- Chemistry Department "S. Cannizzaro", University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy.,Dipartimento di Biologia Ambientale, University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy
| | - Maria Antonietta Loreto
- Chemistry Department "S. Cannizzaro", University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy
| | - Gabriele Magarò
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A., Piazzale della stazione snc, 00071, S. Palomba-Pomezia (Rome), Italy
| | - Giorgina Mangano
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A., Piazzale della stazione snc, 00071, S. Palomba-Pomezia (Rome), Italy
| | - Rinaldo Marini Bettolo
- Chemistry Department "S. Cannizzaro", University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy
| | - Emanuela Masini
- Departments of NEUROFARBA, Section of Pharmacology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy
| | - Martina Miceli
- Department of Science, Section of Nanoscience and Nanotechnology, University of Roma Tre, via della Vasca Navale 79, 00146, Rome, Italy
| | - Luisa Maria Migneco
- Chemistry Department "S. Cannizzaro", University of Rome "La Sapienza", P.le Aldo Moro 5, 00185, Rome, Italy
| | - Marco Vitiello
- Angelini RR&D (Research, Regulatory & Development), Angelini S.p.A., Piazzale della stazione snc, 00071, S. Palomba-Pomezia (Rome), Italy
| |
Collapse
|
4
|
Travelli C, Aprile S, Rahimian R, Grolla AA, Rogati F, Bertolotti M, Malagnino F, di Paola R, Impellizzeri D, Fusco R, Mercalli V, Massarotti A, Stortini G, Terrazzino S, Del Grosso E, Fakhfouri G, Troiani MP, Alisi MA, Grosa G, Sorba G, Canonico PL, Orsomando G, Cuzzocrea S, Genazzani AA, Galli U, Tron GC. Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity. J Med Chem 2017; 60:1768-1792. [DOI: 10.1021/acs.jmedchem.6b01392] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Cristina Travelli
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Silvio Aprile
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Reza Rahimian
- Department
of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
- Department
of Psychiatry and Neuroscience, Faculty of Medicine, Research Center
of the Mental Health Institute of Quebec, Laval University, Quebec, Quebec G1J 2G3, Canada
| | - Ambra A. Grolla
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Federica Rogati
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Mattia Bertolotti
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Floriana Malagnino
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Rosanna di Paola
- Department
of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Via C. Valeria Gazzi, 98100 Messina, Italy
| | - Daniela Impellizzeri
- Department
of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Via C. Valeria Gazzi, 98100 Messina, Italy
| | - Roberta Fusco
- Department
of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Via C. Valeria Gazzi, 98100 Messina, Italy
| | - Valentina Mercalli
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Alberto Massarotti
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Giorgio Stortini
- Department
of Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy
| | - Salvatore Terrazzino
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Erika Del Grosso
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Gohar Fakhfouri
- Department
of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Maria Pia Troiani
- R&D, Angelini Research Center, Piazzale della Stazione, 00040 S. Palomba-Pomezia, Italy
| | | | - Giorgio Grosa
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Giovanni Sorba
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Pier Luigi Canonico
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Giuseppe Orsomando
- Department
of Clinical Sciences (DISCO), Section of Biochemistry, Polytechnic University of Marche, Via Ranieri 67, 60131 Ancona, Italy
| | - Salvatore Cuzzocrea
- Department
of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Via C. Valeria Gazzi, 98100 Messina, Italy
| | - Armando A. Genazzani
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Ubaldina Galli
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| | - Gian Cesare Tron
- Dipartimento
di Scienze del Farmaco, Università degli Studi del Piemonte Orientale “A. Avogadro”, Largo Donegani 2, 28100 Novara, Italy
| |
Collapse
|
5
|
Corso G, Alisi MA, Cazzolla N, Coletta I, Furlotti G, Garofalo B, Mangano G, Mancini F, Vitiello M, Ombrato R. A Novel Multi-step Virtual Screening for the Identification of Human and Mouse mPGES-1 Inhibitors. Mol Inform 2016; 35:358-68. [PMID: 27546040 DOI: 10.1002/minf.201600024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Accepted: 04/21/2016] [Indexed: 11/06/2022]
Abstract
We present here the development of a novel virtual screening protocol combining Structure-based and Ligand-based drug design approaches for the identification of mouse mPGES-1 inhibitors. We used the existing 3D structural data of the murine enzyme to hypothesize the inhibitors binding mode, which was the starting point for docking simulations, shape screening, and pharmacophore hypothesis screening. The protocol allowed the identification of 16 mouse mPGES-1 inhibitors with low micromolar activity, which, notably, also inhibit the human enzyme in the same concentration range. The inhibitors predicted binding mode is expected to be the base for the rational drug design of new potent dual species inhibitors of human and murine mPGES-1.
Collapse
Affiliation(s)
- G Corso
- Angelini Research Center, Angelini S.p.A. P.le della Stazione, snc, I-00071 S. Palomba - Pomezia (RM) -, Italy .
| | - M A Alisi
- Angelini Research Center, Angelini S.p.A. P.le della Stazione, snc, I-00071 S. Palomba - Pomezia (RM) -, Italy
| | - N Cazzolla
- Angelini Research Center, Angelini S.p.A. P.le della Stazione, snc, I-00071 S. Palomba - Pomezia (RM) -, Italy
| | - I Coletta
- Angelini Research Center, Angelini S.p.A. P.le della Stazione, snc, I-00071 S. Palomba - Pomezia (RM) -, Italy
| | - G Furlotti
- Angelini Research Center, Angelini S.p.A. P.le della Stazione, snc, I-00071 S. Palomba - Pomezia (RM) -, Italy
| | - B Garofalo
- Angelini Research Center, Angelini S.p.A. P.le della Stazione, snc, I-00071 S. Palomba - Pomezia (RM) -, Italy
| | - G Mangano
- Angelini Research Center, Angelini S.p.A. P.le della Stazione, snc, I-00071 S. Palomba - Pomezia (RM) -, Italy
| | - F Mancini
- Angelini Research Center, Angelini S.p.A. P.le della Stazione, snc, I-00071 S. Palomba - Pomezia (RM) -, Italy
| | - M Vitiello
- Angelini Research Center, Angelini S.p.A. P.le della Stazione, snc, I-00071 S. Palomba - Pomezia (RM) -, Italy
| | - Rosella Ombrato
- Angelini Research Center, Angelini S.p.A. P.le della Stazione, snc, I-00071 S. Palomba - Pomezia (RM) -, Italy
| |
Collapse
|
6
|
Furlotti G, Alisi MA, Cazzolla N, Dragone P, Durando L, Magarò G, Mancini F, Mangano G, Ombrato R, Vitiello M, Armirotti A, Capurro V, Lanfranco M, Ottonello G, Summa M, Reggiani A. Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders. J Med Chem 2015; 58:8920-37. [PMID: 26486317 DOI: 10.1021/acs.jmedchem.5b01208] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Novel treatments for bipolar disorder with improved efficacy and broader spectrum of activity are urgently needed. Glycogen synthase kinase 3β (GSK-3β) has been suggested to be a key player in the pathophysiology of bipolar disorder. A series of novel GSK-3β inhibitors having the common N-[(1-alkylpiperidin-4-yl)methyl]-1H-indazole-3-carboxamide scaffold were prepared taking advantage of an X-ray cocrystal structure of compound 5 with GSK-3β. We probed different substitutions at the indazole 5-position and at the piperidine-nitrogen to obtain potent ATP-competitive GSK-3β inhibitors with good cell activity. Among the compounds assessed in the in vivo PK experiments, 14i showed, after i.p. dosing, encouraging plasma PK profile and brain exposure, as well as efficacy in a mouse model of mania. Compound 14i was selected for further in vitro/in vivo pharmacological evaluation, in order to elucidate the use of ATP-competitive GSK-3β inhibitors as new tools in the development of new treatments for mood disorders.
Collapse
Affiliation(s)
- Guido Furlotti
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Maria Alessandra Alisi
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Nicola Cazzolla
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Patrizia Dragone
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Lucia Durando
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Gabriele Magarò
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Francesca Mancini
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Giorgina Mangano
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Rosella Ombrato
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Marco Vitiello
- Angelini S.p.A., Angelini Research Center , P.le della Stazione s.n.c., Santa Palomba-Pomezia, 00071 Rome, Italy
| | - Andrea Armirotti
- Drug Discovery and Development Department, Istituto Italiano di Tecnologia , Via Morego 30, 16163 Genova, Italy
| | - Valeria Capurro
- Drug Discovery and Development Department, Istituto Italiano di Tecnologia , Via Morego 30, 16163 Genova, Italy
| | - Massimiliano Lanfranco
- Drug Discovery and Development Department, Istituto Italiano di Tecnologia , Via Morego 30, 16163 Genova, Italy
| | - Giuliana Ottonello
- Drug Discovery and Development Department, Istituto Italiano di Tecnologia , Via Morego 30, 16163 Genova, Italy
| | - Maria Summa
- Drug Discovery and Development Department, Istituto Italiano di Tecnologia , Via Morego 30, 16163 Genova, Italy
| | - Angelo Reggiani
- Drug Discovery and Development Department, Istituto Italiano di Tecnologia , Via Morego 30, 16163 Genova, Italy
| |
Collapse
|
7
|
Alisi MA, Brufani M, Cazzolla N, Ceccacci F, Dragone P, Felici M, Furlotti G, Garofalo B, La Bella A, Lanzalunga O, Leonelli F, Marini Bettolo R, Maugeri C, Migneco LM, Russo V. DPPH radical scavenging activity of paracetamol analogues. Tetrahedron 2012. [DOI: 10.1016/j.tet.2012.09.098] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
8
|
Furlotti G, Alisi MA, Apicella C, Capezzone de Joannon A, Cazzolla N, Costi R, Cuzzucoli Crucitti G, Garrone B, Iacovo A, Magarò G, Mangano G, Miele G, Ombrato R, Pescatori L, Polenzani L, Rosi F, Vitiello M, Di Santo R. Discovery and Pharmacological Profile of New 1H-Indazole-3-carboxamide and 2H-Pyrrolo[3,4-c]quinoline Derivatives as Selective Serotonin 4 Receptor Ligands. J Med Chem 2012; 55:9446-66. [DOI: 10.1021/jm300573d] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
| | | | | | | | | | - Roberta Costi
- Istituto Pasteur—Fondazione
Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Università di Roma,
Piazzale Aldo Moro 5, 00185 Rome, Italy
| | - Giuliana Cuzzucoli Crucitti
- Istituto Pasteur—Fondazione
Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Università di Roma,
Piazzale Aldo Moro 5, 00185 Rome, Italy
| | | | - Alberto Iacovo
- Istituto Pasteur—Fondazione
Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Università di Roma,
Piazzale Aldo Moro 5, 00185 Rome, Italy
| | | | | | - Gaetano Miele
- Istituto Pasteur—Fondazione
Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Università di Roma,
Piazzale Aldo Moro 5, 00185 Rome, Italy
| | | | - Luca Pescatori
- Istituto Pasteur—Fondazione
Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Università di Roma,
Piazzale Aldo Moro 5, 00185 Rome, Italy
| | | | - Federica Rosi
- Istituto Pasteur—Fondazione
Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Università di Roma,
Piazzale Aldo Moro 5, 00185 Rome, Italy
| | | | - Roberto Di Santo
- Istituto Pasteur—Fondazione
Cenci Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, “Sapienza” Università di Roma,
Piazzale Aldo Moro 5, 00185 Rome, Italy
| |
Collapse
|
9
|
Finetti F, Terzuoli E, Bocci E, Coletta I, Polenzani L, Mangano G, Alisi MA, Cazzolla N, Giachetti A, Ziche M, Donnini S. Pharmacological inhibition of microsomal prostaglandin E synthase-1 suppresses epidermal growth factor receptor-mediated tumor growth and angiogenesis. PLoS One 2012; 7:e40576. [PMID: 22815767 PMCID: PMC3399882 DOI: 10.1371/journal.pone.0040576] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2012] [Accepted: 06/11/2012] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND Blockade of Prostaglandin (PG) E(2) production via deletion of microsomal Prostaglandin E synthase-1 (mPGES-1) gene reduces tumor cell proliferation in vitro and in vivo on xenograft tumors. So far the therapeutic potential of the pharmacological inhibition of mPGES-1 has not been elucidated. PGE(2) promotes epithelial tumor progression via multiple signaling pathways including the epidermal growth factor receptor (EGFR) signaling pathway. METHODOLOGY/PRINCIPAL FINDINGS Here we evaluated the antitumor activity of AF3485, a compound of a novel family of human mPGES-1 inhibitors, in vitro and in vivo, in mice bearing human A431 xenografts overexpressing EGFR. Treatment of the human cell line A431 with interleukin-1beta (IL-1β) increased mPGES-1 expression, PGE(2) production and induced EGFR phosphorylation, and vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) expression. AF3485 reduced PGE(2) production, both in quiescent and in cells stimulated by IL-1β. AF3485 abolished IL-1β-induced activation of the EGFR, decreasing VEGF and FGF-2 expression, and tumor-mediated endothelial tube formation. In vivo, in A431 xenograft, AF3485, administered sub-chronically, decreased tumor growth, an effect related to inhibition of EGFR signalling, and to tumor microvessel rarefaction. In fact, we observed a decrease of EGFR phosphorylation, and VEGF and FGF-2 expression in tumours explanted from treated mice. CONCLUSION Our work demonstrates that the pharmacological inhibition of mPGES-1 reduces squamous carcinoma growth by suppressing PGE(2) mediated-EGFR signalling and by impairing tumor associated angiogenesis. These results underscore the potential of mPGES-1 inhibitors as agents capable of controlling tumor growth.
Collapse
Affiliation(s)
- Federica Finetti
- Department of Biotechnology, University of Siena, Via Aldo Moro, 2, Siena, and Istituto Toscano Tumori (ITT), Italy
| | - Erika Terzuoli
- Department of Biotechnology, University of Siena, Via Aldo Moro, 2, Siena, and Istituto Toscano Tumori (ITT), Italy
| | - Elena Bocci
- Department of Biotechnology, University of Siena, Via Aldo Moro, 2, Siena, and Istituto Toscano Tumori (ITT), Italy
| | - Isabella Coletta
- Angelini Research Center–A.C.R.A.F. S.p.A., Piazzale della stazione, S. Palomba-Pomezia (Rome), Italy
| | - Lorenzo Polenzani
- Angelini Research Center–A.C.R.A.F. S.p.A., Piazzale della stazione, S. Palomba-Pomezia (Rome), Italy
| | - Giorgina Mangano
- Angelini Research Center–A.C.R.A.F. S.p.A., Piazzale della stazione, S. Palomba-Pomezia (Rome), Italy
| | - Maria Alessandra Alisi
- Angelini Research Center–A.C.R.A.F. S.p.A., Piazzale della stazione, S. Palomba-Pomezia (Rome), Italy
| | - Nicola Cazzolla
- Angelini Research Center–A.C.R.A.F. S.p.A., Piazzale della stazione, S. Palomba-Pomezia (Rome), Italy
| | - Antonio Giachetti
- Department of Biotechnology, University of Siena, Via Aldo Moro, 2, Siena, and Istituto Toscano Tumori (ITT), Italy
| | - Marina Ziche
- Department of Biotechnology, University of Siena, Via Aldo Moro, 2, Siena, and Istituto Toscano Tumori (ITT), Italy
- * E-mail: (MZ); (SD)
| | - Sandra Donnini
- Department of Biotechnology, University of Siena, Via Aldo Moro, 2, Siena, and Istituto Toscano Tumori (ITT), Italy
- * E-mail: (MZ); (SD)
| |
Collapse
|
10
|
Bruno A, Di Francesco L, Coletta I, Mangano G, Alisi MA, Polenzani L, Milanese C, Anzellotti P, Ricciotti E, Dovizio M, Di Francesco A, Tacconelli S, Capone ML, Patrignani P. Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. Biochem Pharmacol 2010; 79:974-81. [DOI: 10.1016/j.bcp.2009.11.011] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2009] [Revised: 11/06/2009] [Accepted: 11/09/2009] [Indexed: 01/20/2023]
|
11
|
Alisi MA, Brufani M, Filocamo L, Cellai L, Iannelli MA, Cesta MC, Lappa S. Synthesis of acylphosphonyl analogues of phosphatidyl-myo-inositol as inhibitors of phosphatidylinositol-specific phospholipase C. Carbohydr Res 1994; 265:139-43. [PMID: 7834650 DOI: 10.1016/0008-6215(94)00213-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- M A Alisi
- Dipartimento di Scienze Biochimiche, A. Rossi Fanelli, Università La Sapienza, Roma, Italy
| | | | | | | | | | | | | |
Collapse
|